← Back to Search

Special Care Service for Lung Cancer

N/A

Waitlist Available

Led By Brian Henick, MD

Research Sponsored by Columbia University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age≥ 18 years

Confirmed NSCLC diagnosis

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2.5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial studies if a special care service can help cancer patients from minority backgrounds get better treatment and reduce how much they need to go to the doctor.

Who is the study for?

This trial is for adults over 18 with confirmed non-small cell lung cancer (NSCLC) who are receiving immunotherapy and identify as part of an ethnic minority or underserved group. They must understand the study and agree to participate. Those in other clinical trials or with conditions that may hinder participation cannot join.

What is being tested?

The Apricity C.A.R.E. Program is being tested to see if it can improve treatment results for NSCLC patients from racial/ethnic minorities on immunotherapy, aiming to reduce their need for frequent healthcare visits.

What are the potential side effects?

Since this trial focuses on a care service program rather than a drug, there aren't direct side effects like those seen with medications. However, interactions with the healthcare system could change.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have been diagnosed with non-small cell lung cancer.

Select...

I am being treated with drugs that boost my immune system to fight cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2.5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2.5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2.5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Mean Likert-type scale score

Percent of study patients who experienced treatment delay/discontinuation

Secondary study objectives

Number of interactions with the care team and utilization

Number of interviews/surveys completed

Percent of study patients who experience a severe irAE (grade 3 or higher).

+2 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention ArmExperimental Treatment1 Intervention

Participants are provided with ApricityRx digital solution with pulse oximeters and 24/7 C.A.R.E. (Cancer Adverse event Rapid Evaluation) to monitor and capture ePRO, identify onset or progression of symptoms verified by nurse triage, trigger intervention by the study team.

Group II: Control ArmActive Control1 Intervention

Clinicians will monitor NSCLC patients on ICIs for irAEs as a standard of care using routine practices.

0 / 3Eligibility criteria met